The proven efficacy and safety of biologics has added to the armamentarium of treatment options for patients suffering from psoriasis and PsA. As more biologic therapies enter the marketplace, the opportunity for improved prognosis and symptom control will benefit patients and improve their quality of life. Efficacy and safety, patient comorbidities, patient preference and quality life need to be taken into consideration when dermatologists are prescribing treatment. Continuing education on current and future medications is also needed so dermatologists and other clinicians properly manage patients living with psoriasis.
1. National Psoriasis Foundation Web site. Psoriasis statistics. http://www.psoriasis.org/research/science-of-psoriasis/statistics. Accessed November 17, 2015.
2. National Psoriasis Foundation. The Psoriasis and Psoriatic Arthritis Pocket Guide: Treatment Options and Patient Management. 3rd ed. Portland, OR; 2009.
3. Van de Kerkhof PC, Reich K, Kavanaugh A, et al. J Eur Acad Dermatol Venereol. 2015;29(10):2002-2010.
4. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;36(15):496-509.
5. Feldman SR, Zhao Y, Shi L, Tran ME. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Mang Care Spec Pharm. 2015;21(10):874-888.
6. Zhang M, Brenneman SK, Carter CT, et al. Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis. Patient Pref Adherence. 2015;8:777-784.
7. Donigan JM, Pascoe VL, Kimball AB. Psoriasis and herpes simplex virus are highly stigmatizing compared with other common dermatologic conditions: A survey-based study. J Am Acad Dermato l. 2015;73(3):525-526.
8. Parisi R, Symmons DR, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385.
9. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850.
10. Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: A systematic review. JAMA Dermatol. 2015;151(6):651-658.
11. Gaffen SL. Structure and signaling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8):556-567.
12. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187(1):490-500.
13. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244-279.
14. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125-130.
15. Awasthi A, Kuchroo VK. Th17 cells: from precursors to players in inflammation and infection. Int Immunol. 2009;21(5):489-498.
16. National Psoriasis Foundation. Moderate to Severe Psoriasis: Biologic Drugs. http://www.psoriasis.org/about-psoriasis/treatments/biologics. Accessed November 16, 2015.
17. Humira [prescribing information]. North Chicago, IL: AbbVie Inc; 2015.
18. Cimzia [prescribing information]. Smyrna, GA: UCB Inc; 2013.
19. Enbrel [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2015.
20. Simponi [prescribing information]. Horsham, PA: Janssen Biotech Inc; 2013.
21. Remicade [prescribing information]. Horsham, PA: Janssen Biotech Inc; 2015.
22. Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.
23. Stelara. [prescribing information]. Horsham, PA: Janssen Biotech Inc; 2014.
24. Menter A, Korman NJ, Elmets CA. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451-485.
25. Mansouri Y, Goldenberg G. Biologic safety in psoriasis: review of long-term safety data. J Clin Aesthet Dermatol. 2015;8(2):30-42.
26. Menter A, Thaçi D, Papp KA, et al. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol. 2015;73(3):410-419.
27. Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perodok RJ, Sasso EH. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther. 2010;12(3):R113.
28. Mease P, Deodhar A, Fleischmann R, et al. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open. 2015;1(1):e000119.
29. Papp KA, Poulin Y, Bissonnette R, et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol. 2012;66(2):e33-45.
30. Kavanaugh A, van der Heijde D, Beutler A, et al. Patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy demonstrate less radiographic progression: Results through 5 years of the randomized, placebo-controlled, GO-REVEAL study. Arthritis Care Res. Published online ahead of print March 16, 2015.
31. Wang J, Zhan Q, Zhang L. A systematic review on the efficacy and safety of infliximab in patients with psoriasis. Hum Vaccin Immunother. Published online ahead of print November 3, 2015.
32. Langley RG, Elewsku BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.
33. Langley RG, Lebwohol M, Krueger GG, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371-1383.
34. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with ac tive psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990-999.
35. National Psoriasis Foundations. Biologic Drugs: Fact Sheets. http://www.psoriasis.org/about-psoriasis/treatments/biologics/resources. Accessed November 16, 2015. 36. Townsend M, Stober BE. Rare side effects of biologics: part 1. The Dermatologist. 2013;21(11):28-32.
37. Townsend M, Stober BE. Rare side effects of biologics: part 2. The Dermatologist. 2013;21(12):30-34.
38. Levy LL, Solomon SM, Emer JJ. Biologics in the treatment of psoriasis and emerging new therapies in the pipeline. Psoriasis: Targets and Therapy. 2012;2:29-43.
39. Cheng J, Feldman SR. The cost of biologics for psoriasis is increasing. Drug Context. 2014;3:212266.
40. Kamangar F, Isip L, Bhutani T, et al. How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center. J Dermatolog Treat. 2013;24(1):13-24.
41. Strohal R, Prinz JC, Girolomoni G, Nast A. A patient-centered approach to biological treatment decision making for psoriasis: an expert consensus. J Eur Acad Dermatol Venereol. Published online ahead of print September 14, 2015.
42. Feely MA, Smith BL, Weinberg JM. Novel psoriasis therapies and patient outcomes, part 2: biologic treatments. Cutis. 2015;95(5):282-290.
43. Boehringer Ingelheim’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study [news release]. Ridgefield, CT: Boehringer Ingelheim GmbH; October 8, 2015. https://www. boehringer-ingelheim.com/news/news_releases/press_releases/2015/08_oktober_2015_immunology.html. Accessed November 19, 2015.